These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 24252823)

  • 1. Psychopharmacology of the negative symptoms: current status and prospects for progress.
    Davis MC; Horan WP; Marder SR
    Eur Neuropsychopharmacol; 2014 May; 24(5):788-99. PubMed ID: 24252823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Negative symptoms in schizophrenia: new pharmacological approaches].
    Lodovighi MA; Palomba A; Belzeaux R; Adida M; Azorin JM
    Encephale; 2015 Dec; 41(6 Suppl 1):6S41-9. PubMed ID: 26776392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment.
    Millan MJ; Fone K; Steckler T; Horan WP
    Eur Neuropsychopharmacol; 2014 May; 24(5):645-92. PubMed ID: 24820238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.
    Miyamoto S; Miyake N; Jarskog LF; Fleischhacker WW; Lieberman JA
    Mol Psychiatry; 2012 Dec; 17(12):1206-27. PubMed ID: 22584864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternative pharmacologic targets for the treatment of schizophrenia: results from phase I and II trials.
    Miyamoto S; Jarskog LF; Fleischhacker WW
    Curr Opin Psychiatry; 2013 Mar; 26(2):158-65. PubMed ID: 23286991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The selective glycine uptake inhibitor org 25935 as an adjunctive treatment to atypical antipsychotics in predominant persistent negative symptoms of schizophrenia: results from the GIANT trial.
    Schoemaker JH; Jansen WT; Schipper J; Szegedi A
    J Clin Psychopharmacol; 2014 Apr; 34(2):190-8. PubMed ID: 24525661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting glutamate system for novel antipsychotic approaches: relevance for residual psychotic symptoms and treatment resistant schizophrenia.
    de Bartolomeis A; Sarappa C; Magara S; Iasevoli F
    Eur J Pharmacol; 2012 May; 682(1-3):1-11. PubMed ID: 22387855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological approaches to treating negative symptoms: a review of clinical trials.
    Arango C; Garibaldi G; Marder SR
    Schizophr Res; 2013 Nov; 150(2-3):346-52. PubMed ID: 23938176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sertindole for the treatment of schizophrenia.
    Azorin JM; Kaladjian A; Fakra E; Adida M
    Expert Opin Pharmacother; 2010 Dec; 11(18):3053-64. PubMed ID: 21080854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological treatment of negative symptoms in schizophrenia.
    Möller HJ; Czobor P
    Eur Arch Psychiatry Clin Neurosci; 2015 Oct; 265(7):567-78. PubMed ID: 25895634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Executive function in schizophrenia: what impact do antipsychotics have?
    O'Grada C; Dinan T
    Hum Psychopharmacol; 2007 Aug; 22(6):397-406. PubMed ID: 17579928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Managing Negative Symptoms of Schizophrenia: How Far Have We Come?
    Kantrowitz JT
    CNS Drugs; 2017 May; 31(5):373-388. PubMed ID: 28397113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or cul-de-sac?
    Buckley PF; Stahl SM
    Acta Psychiatr Scand; 2007 Feb; 115(2):93-100. PubMed ID: 17244172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dissecting negative symptoms in schizophrenia: opportunities for translation into new treatments.
    Foussias G; Siddiqui I; Fervaha G; Agid O; Remington G
    J Psychopharmacol; 2015 Feb; 29(2):116-26. PubMed ID: 25516370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Schizophrenia: moving beyond monoamine antagonists.
    Conn PJ; Tamminga C; Schoepp DD; Lindsley C
    Mol Interv; 2008 Apr; 8(2):99-107. PubMed ID: 18403654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study.
    Umbricht D; Alberati D; Martin-Facklam M; Borroni E; Youssef EA; Ostland M; Wallace TL; Knoflach F; Dorflinger E; Wettstein JG; Bausch A; Garibaldi G; Santarelli L
    JAMA Psychiatry; 2014 Jun; 71(6):637-46. PubMed ID: 24696094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential serotonergic agents for the treatment of schizophrenia.
    Garay RP; Bourin M; de Paillette E; Samalin L; Hameg A; Llorca PM
    Expert Opin Investig Drugs; 2016; 25(2):159-70. PubMed ID: 26576669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacotherapy of schizophrenia: ploypharmacy approaches.
    Rahiminejad F; Akhondzadeh S
    Acta Med Iran; 2010; 48(4):203-8. PubMed ID: 21279929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Problems in evaluating new antipsychotic drugs].
    Fleischhacker WW
    Wien Med Wochenschr; 1998; 148(11-12):266-72. PubMed ID: 9746969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of schizophrenia negative symptoms: future prospects.
    Erhart SM; Marder SR; Carpenter WT
    Schizophr Bull; 2006 Apr; 32(2):234-7. PubMed ID: 16492797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.